CA2195668A1 - Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression - Google Patents
Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expressionInfo
- Publication number
- CA2195668A1 CA2195668A1 CA002195668A CA2195668A CA2195668A1 CA 2195668 A1 CA2195668 A1 CA 2195668A1 CA 002195668 A CA002195668 A CA 002195668A CA 2195668 A CA2195668 A CA 2195668A CA 2195668 A1 CA2195668 A1 CA 2195668A1
- Authority
- CA
- Canada
- Prior art keywords
- regulation
- heavy chain
- mhc class
- human cytomegalovirus
- identification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 5
- 230000003828 downregulation Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 101150085955 US11 gene Proteins 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 238000012217 deletion Methods 0.000 abstract 2
- 108010027410 Adenovirus E3 Proteins Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
Abstract
Infection of human fibroblast cells with human cytomegalovirus (HCMV) causes down-regulation of cell surface expression of MHC
class I. The present invention is directed to a mutant with a 9-kb deletion in the S component of the HCMV genome (including open reading frames IRS1-US9 and US11) which fails to down-regulate class I heavy chains. By examining the phenotypes of mutants with smaller deletions with this portion of the HCMV genome, a 7-kb region containing at least 9 open reading frames was shown to contain the genes required for reduction in heavy chain expression. Furthermore, it was determined that two subregions (A and B) of the 7-kb region each contained genes which were sufficient to cause heavy chain down-regulation. In subregion B, the US11 gene product is involved.
It encodes an endoglycosidase H-sensitive glycoprotein which is intracytoplasmic, similar to the adenovirus type 2 E3-19K glycoprotein which inhibits surface expression of class I heavy chains.
class I. The present invention is directed to a mutant with a 9-kb deletion in the S component of the HCMV genome (including open reading frames IRS1-US9 and US11) which fails to down-regulate class I heavy chains. By examining the phenotypes of mutants with smaller deletions with this portion of the HCMV genome, a 7-kb region containing at least 9 open reading frames was shown to contain the genes required for reduction in heavy chain expression. Furthermore, it was determined that two subregions (A and B) of the 7-kb region each contained genes which were sufficient to cause heavy chain down-regulation. In subregion B, the US11 gene product is involved.
It encodes an endoglycosidase H-sensitive glycoprotein which is intracytoplasmic, similar to the adenovirus type 2 E3-19K glycoprotein which inhibits surface expression of class I heavy chains.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/282,696 US5846806A (en) | 1994-07-29 | 1994-07-29 | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US08/282,696 | 1994-07-29 | ||
PCT/US1995/009607 WO1996004383A1 (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2195668A1 true CA2195668A1 (en) | 1996-02-15 |
CA2195668C CA2195668C (en) | 2004-09-21 |
Family
ID=23082718
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002195668A Expired - Fee Related CA2195668C (en) | 1994-07-29 | 1995-07-28 | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression |
CA002328638A Abandoned CA2328638A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
CA002196207A Expired - Fee Related CA2196207C (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002328638A Abandoned CA2328638A1 (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
CA002196207A Expired - Fee Related CA2196207C (en) | 1994-07-29 | 1995-07-31 | Identification of a human cytomegalovirus gene involved in down-regulation of mhc class i heavy chain expression |
Country Status (11)
Country | Link |
---|---|
US (6) | US5846806A (en) |
EP (2) | EP0775209A1 (en) |
JP (2) | JP4036469B2 (en) |
KR (2) | KR970704884A (en) |
AU (2) | AU709552B2 (en) |
CA (3) | CA2195668C (en) |
FI (2) | FI970352A (en) |
MX (1) | MX9700676A (en) |
NO (2) | NO970369L (en) |
NZ (2) | NZ290718A (en) |
WO (2) | WO1996004383A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032605A1 (en) * | 1996-03-08 | 1997-09-12 | Massachusetts Institute Of Technology | Cytomegalovirus nucleic acids encoding proteins having normal or altered class i mhc binding and treatment of diseases |
PT966301E (en) * | 1996-07-31 | 2005-06-30 | Ortho Mcneil Pharm Inc | IDENTIFICATION OF HUMAN CITOMEGALOVIRUS GENES INVOLVED IN THE NEGATIVE ADJUSTMENT OF MHC HEAVY CHAIN EXPRESSION CLASS I |
WO1998031813A1 (en) * | 1997-01-17 | 1998-07-23 | Roche Diagnostics Gmbh | Inhibitors of antigen presentation by mhc class i molecules |
WO1998047914A2 (en) * | 1997-04-18 | 1998-10-29 | Roche Diagnostics Gmbh | Us6 gene from the human cytomegalovirus (hcmv) |
EP1045920A1 (en) * | 1998-01-14 | 2000-10-25 | Human Gene Therapy Research Institute | Nucleotide expression systems with reduced immunogenicity for use in gene therapy |
US6100008A (en) * | 1998-09-14 | 2000-08-08 | Ppg Industries Ohio, Inc. | Positive photoresist with improved contrast ratio and photospeed |
WO2000046361A1 (en) * | 1999-02-02 | 2000-08-10 | Oregon Health Sciences University | Inhibition of the mhc class ii antigen presentation pathway and presentation to cd4+ cells |
WO2002018954A2 (en) | 2000-08-30 | 2002-03-07 | Chemocentryx, Inc. | Inhibition of cmv infection and dissemination |
WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
US20030118568A1 (en) * | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
KR20050093003A (en) * | 2004-03-17 | 2005-09-23 | 이재본 | Micro turbine generator |
JP2010517544A (en) | 2007-02-07 | 2010-05-27 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | Recombinant antigen of human cytomegalovirus (HCMV) |
WO2009073330A2 (en) * | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
CA2793959C (en) * | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
PT2772265T (en) | 2010-05-14 | 2018-04-20 | Univ Oregon Health & Science | Recombinant hcmv and rhcmv vectors and uses thereof |
AU2012267786B2 (en) | 2011-06-10 | 2017-08-03 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
WO2014138209A1 (en) | 2013-03-05 | 2014-09-12 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of t cell targeting |
MA39818A (en) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof |
BR112017000696B1 (en) | 2014-07-16 | 2023-10-03 | Oregon Health & Science University | ISOLATED POLYNUCLEOTIDE |
CN114317611A (en) * | 2015-02-10 | 2022-04-12 | 俄勒冈健康与科学大学 | Methods and compositions useful for generating atypical CD8+ T cell responses |
US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
JP2019531745A (en) | 2016-10-18 | 2019-11-07 | オレゴン ヘルス アンド サイエンス ユニバーシティ | Cytomegalovirus vector that induces T cells restricted by major histocompatibility complex E molecules |
EP3697806A4 (en) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11857622B2 (en) | 2020-06-21 | 2024-01-02 | Pfizer Inc. | Human cytomegalovirus GB polypeptide |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4058598A (en) * | 1974-10-18 | 1977-11-15 | Harold Stern | Cytomegalovirus attenuation method and vaccine |
US4689225A (en) * | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
US4877612A (en) * | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
US4877737A (en) * | 1985-09-06 | 1989-10-31 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
WO1988010311A1 (en) * | 1987-06-26 | 1988-12-29 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
AU3550489A (en) * | 1988-05-09 | 1989-11-29 | Children's Hospital Incorporated, The | Vectors encoding hcmv glycoprotein and expression products |
SG49046A1 (en) * | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
-
1994
- 1994-07-29 US US08/282,696 patent/US5846806A/en not_active Expired - Fee Related
-
1995
- 1995-06-02 US US08/459,586 patent/US5720957A/en not_active Expired - Fee Related
- 1995-06-02 US US08/458,544 patent/US5753476A/en not_active Expired - Fee Related
- 1995-07-28 CA CA002195668A patent/CA2195668C/en not_active Expired - Fee Related
- 1995-07-28 WO PCT/US1995/009607 patent/WO1996004383A1/en not_active Application Discontinuation
- 1995-07-28 JP JP50665896A patent/JP4036469B2/en not_active Expired - Fee Related
- 1995-07-28 EP EP95927533A patent/EP0775209A1/en not_active Withdrawn
- 1995-07-28 NZ NZ290718A patent/NZ290718A/en unknown
- 1995-07-28 AU AU31535/95A patent/AU709552B2/en not_active Ceased
- 1995-07-31 MX MX9700676A patent/MX9700676A/en unknown
- 1995-07-31 WO PCT/US1995/009799 patent/WO1996004384A1/en not_active Application Discontinuation
- 1995-07-31 AU AU32745/95A patent/AU708983B2/en not_active Ceased
- 1995-07-31 EP EP95929364A patent/EP0772681A1/en not_active Withdrawn
- 1995-07-31 NZ NZ291571A patent/NZ291571A/en unknown
- 1995-07-31 CA CA002328638A patent/CA2328638A1/en not_active Abandoned
- 1995-07-31 CA CA002196207A patent/CA2196207C/en not_active Expired - Fee Related
- 1995-07-31 US US08/509,214 patent/US5843458A/en not_active Expired - Fee Related
- 1995-07-31 JP JP8506737A patent/JPH10506268A/en not_active Ceased
-
1997
- 1997-01-28 NO NO970369A patent/NO970369L/en not_active Application Discontinuation
- 1997-01-28 NO NO970370A patent/NO970370L/en not_active Application Discontinuation
- 1997-01-28 FI FI970352A patent/FI970352A/en unknown
- 1997-01-28 FI FI970351A patent/FI970351A0/en unknown
- 1997-01-29 KR KR1019970700612A patent/KR970704884A/en not_active Application Discontinuation
- 1997-01-29 KR KR1019970700611A patent/KR970704883A/en not_active Application Discontinuation
- 1997-10-07 US US08/946,598 patent/US5906935A/en not_active Expired - Fee Related
-
1998
- 1998-03-16 US US09/039,802 patent/US5908780A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH10506268A (en) | 1998-06-23 |
WO1996004383A1 (en) | 1996-02-15 |
NO970370D0 (en) | 1997-01-28 |
NO970369D0 (en) | 1997-01-28 |
AU709552B2 (en) | 1999-09-02 |
AU3153595A (en) | 1996-03-04 |
CA2195668C (en) | 2004-09-21 |
CA2196207A1 (en) | 1996-02-15 |
FI970352A0 (en) | 1997-01-28 |
US5846806A (en) | 1998-12-08 |
AU3274595A (en) | 1996-03-04 |
JP4036469B2 (en) | 2008-01-23 |
NO970369L (en) | 1997-03-21 |
EP0772681A1 (en) | 1997-05-14 |
KR970704883A (en) | 1997-09-06 |
CA2196207C (en) | 2002-04-30 |
KR970704884A (en) | 1997-09-06 |
US5753476A (en) | 1998-05-19 |
FI970352A (en) | 1997-01-28 |
NZ290718A (en) | 1999-03-29 |
US5843458A (en) | 1998-12-01 |
US5906935A (en) | 1999-05-25 |
MX9700710A (en) | 1997-09-30 |
NO970370L (en) | 1997-03-24 |
FI970351A (en) | 1997-01-28 |
US5908780A (en) | 1999-06-01 |
JPH10503378A (en) | 1998-03-31 |
AU708983B2 (en) | 1999-08-19 |
NZ291571A (en) | 1999-01-28 |
CA2328638A1 (en) | 1996-02-15 |
MX9700676A (en) | 1997-04-30 |
US5720957A (en) | 1998-02-24 |
EP0775209A1 (en) | 1997-05-28 |
FI970351A0 (en) | 1997-01-28 |
WO1996004384A1 (en) | 1996-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2195668A1 (en) | Identification of a human cytomegalovirus gene region involved in down-regulation of mhc class i heavy chain expression | |
ATE396274T1 (en) | HERPES SIMPLEX VIRUS STRAINS | |
AU2853395A (en) | Recombinant vectors derived from adenovirus for use in gene therapy | |
GR3021426T3 (en) | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication | |
GB2234972B (en) | Herpes simplex virus type 1 mutant | |
WO1995027071A3 (en) | An adenovirus supervector system | |
AU3498989A (en) | Non-linear genetic algorithms for solving problems | |
AU585126B2 (en) | Recombinant herpes simplex viruses, vaccines and methods | |
IL113955A0 (en) | The cytoplasmic inhibition of gene expression | |
AU8221191A (en) | Probes for detecting mutant p53 | |
WO1992017152A3 (en) | Method for detecting and treating alzheimer's disease | |
NZ334147A (en) | Immortalised cell lines derived from chicken embryonic fibroblasts and having a population doubling rate of 0.6 to 1.2 population doublings per day | |
CA2146734A1 (en) | Method for long term subculture of dermal papilla cells | |
FI963924A0 (en) | Gene that gives the yeast the ability to flocculate and gene product | |
AU5787490A (en) | Process for reducing the crystal size of ondanestron hydrochloride dihydrate | |
CA2095109A1 (en) | Process for production of exogenous gene or its product in plant cells | |
GB2359083A (en) | Mutant herpes simplex viruses and uses thereof | |
WO1999060138A3 (en) | Regulated expression of pkc and/or srb1/psa1 in yeast | |
ATE190663T1 (en) | CD69 - TRANSCRIPTION REGULATORY ELEMENTS | |
EP1566444A3 (en) | Yield-related genes | |
Zhou et al. | Development and Improvement of SY High-Rigid Rolling Mill | |
EP0828005A3 (en) | Apoptotic agents for tumor cells of the nervous system | |
AU3512793A (en) | Process for the expression of herpes simplex virus type 1 glycoprotein I and methods of use | |
STRAIN | THE FOLLOWING articles have been accepted for publication in Experimental Gerontology and will appear in forthcoming issues of this journal. | |
AU4943296A (en) | Leveller bar for coke ovens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |